All patients
subjects at risk
hydroxychloroquine in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
0.80 [0.52 ; 1.24 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable deathsdetailed results Duke University hydroxychloroquine/azithromycine, 2020 0.50 [0.01; 19.56]
Galan, 2021 (REV) 1.06 [0.58; 1.95]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
0.88 [0.62 ; 1.25 ] Duke University hydroxychloroquine/azithromycine, 2020, Galan, 2021 (REV), HYDRA (Hernandez-Cardenas), 2021 3 0% 387 moderate not evaluable deaths (time to event analysis only)detailed results Galan, 2021 (REV) 1.06 [0.58; 1.95]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
0.88 [0.62 ; 1.26 ] Galan, 2021 (REV), HYDRA (Hernandez-Cardenas), 2021 2 0% 382 moderate not evaluable clinical improvement (time to event analysis only)detailed results HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
1.05 [0.74 ; 1.48 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable hospital dischargedetailed results HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
1.01 [0.72 ; 1.42 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable mechanical ventilationdetailed results Galan, 2021 (REV) 7.21 [1.40; 37.04]
7.21 [1.40 ; 37.04 ] Galan, 2021 (REV) 1 0% 168 NA not evaluable ICU admissiondetailed results Galan, 2021 (REV) 0.70 [0.33; 1.48]
0.70 [0.33 ; 1.48 ] Galan, 2021 (REV) 1 0% 168 NA not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-09 23:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 657,832
- roots T: 290